Focal Point Pharmaceuticals, Inc. closed on $150,000 equity offering

Focal Point Pharmaceuticals, Inc. completed its $150,000 equity offering which started this month. The non-brokered private placement was subscribed by two investors. This is the first known offering initiated by the company on the US private placement market.

As Focal Point is in stealth mode, it is unclear what its line of business will exactly be though it seems to be related to pharmaceutical compound commercialization. Focal Point is tightly linked to a company called Hapten Sciences where Ray Hage and Gary Prosterman are currently CEO and Chairman. Both companies share the same address. Hapten Sciences has licensed a compound developed by ElSohly Laboratories Inc. and University of Mississippi pharmaceutical researchers to prevent reactions to poison ivy, oak and sumac.

The company, headquartered in Memphis TN, is led by Raymond “Ray” J. Hage Jr.(President) and Gary Prosterman (Chairman).

Offering recap:
Status: Completed/Final close
Company: Focal Point Pharmaceuticals, Inc.
Industry: Pharmaceuticals
Amount offered: $150,000
Amount placed: $150,000


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s